Participants will meet at 6:30 AM in front of the conference venue site for a 30 minute run around Copenhagen. Registration is necessary and can be done here. Co-organiser: Vivlion

Workshop: Tools

This workshop will focus on discussing the advantages and disadvantages of different gene-editing technologies and how to select the right one for your approach. We will discuss the following topics: - Comparing CRISPR-mediated knockout and knock-in strategies such as homologous recombination, HITI and MMEJ with novel, DSB-free technologies such as base- and prime editing, focusing on the ideal uses of each technology and their advantages and disadvantages. - How to decide between different Cas9 and base-editor variants depending on the context of your experiments. - Use of protein, RNA or plasmid formulations for Cas9 transfection into cells.

Workshop: Delivery

This workshop will focus on discussing the difficulties that arise when trying to deliver Cas9 into cells or specific tissues, and the different delivery technologies that currently exist. We will discuss the following topics: - In vitro CRISPR delivery systems for efficient transfection of CRISPR reagents in different cell types. - Viral delivery systems and their applications and limitations for in vivo CRISPR delivery. - Non-viral delivery systems for transient activity of CRISPR in target tissues. - Hurdles, bottlenecks and future perspectives for CRISPR delivery and its clinical relevance.

Samantha Maragh, Dr. Leader, Genome Editing Program National Institute of Standards & Technology (NIST), USA. Attila Sebe, MD, PhD. Clinical Assessor Advanced Therapy Medicinal Products (ATMPs) Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Division of Haematology, Cell and Gene Therapy, Germany. Lotte Dahl Nissen, MSc, Ph.D. Non-clinical Assessor Quality Assessment & Clinical Trials Danish Medicines Agency (DKMA), Denmark. Veronika Jekerle, PhD. Head of Pharmaceutical Quality Human Medicines European Medicines Agency (EMA). Moderator: Rebecca Roberts, Ph.D., CRISPR Medicine News

Track 3: Safety

Chairs: Toni Cathomen (University of Freiburg) and Roberto Nitsch (AstraZeneca)

Track 1: Tools
Track 2: Delivery

Chairs: Marcello Maresca (AstraZeneca) and Anna Cereseto (University of Trento, Italy)

Track 4: Functional Genomics

Chairs: Manuel Kaulich (Goethe University Frankfurt) and Bernhard Schmierer (Karolinska Institute, Sweden)

Track 5: Pre-clinical
Track 6: Clinical Trials

Chairs: Alessia Cavazza (University College London) and Waseem Qasim (UCL Great Ormond Street Institute of Child Health)

Track 4: Functional Genomics

Chairs: Bernhard Schmierer (Karolinska Institute, Sweden) and Manuel Kaulich (Goethe University Frankfurt)

Track 3: Safety

Chairs: Toni Cathomen (University of Freiburg, Germany) and Roberto Nitsch (AstraZeneca)

Track 5: Pre-clinical
Track 6: Clinical Trials

Chairs: Waseem Qasim (UCL Great Ormond Street Institute of Child Health) and Alessia Cavazza (University College London)

Track 1: Tools
Track 2: Delivery

Chairs: Anna Cereseto (University of Trento, Italy) and Marcello Maresca (AstraZeneca)